Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan

Vaccine

Volumn 27, Issue 12, 2009, Pages 1858-1862

  Kao, Jung Ta ^a,b   Wang, Jing Houng ^a   Hung, Chao Hung ^a   Yen, Yi Hao ^a   Hung, Shu Fen ^a   Hu, Tsung Hui ^a   Lee, Chuan Mo ^a   Lu, Sheng Nan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Anamnestic response; Hepatitis B virus; Plasma derived vaccine; Recombinant vaccine

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LGVAC B; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NEWBORN; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RURAL POPULATION; SCHOOL CHILD; SEROEPIDEMIOLOGY; SEROPREVALENCE; TAIWAN; TREATMENT RESPONSE;

ADOLESCENT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ENDEMIC DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; INFANT, NEWBORN; MALE; TAIWAN; VACCINES, SYNTHETIC;

EID: 61349124806     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.027     Document Type: Article

References (31)

1. Chen D.S., Hsu N.H., Sung J.L., Hsu T.C., Hsu S.T., Kuo Y.T., et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 257 (1987) 2597-2603
2. Mast E.E., Weinbaum C.M., Fiore A.E., Alter M.J., Bell B.P., Finelli L., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 55 (2006) 1-33
3. Boxall E.H., Sira A., El-Shuhkri J.N., and Kelly D.A. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 190 (2004) 1264-1269
4. Ni Y.H., Chang M.H., Huang L.M., Chen H.L., Hsu H.Y., Chiu T.Y., et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 135 (2001) 796-800
5. Wang L.Y., Hu C.T., Ho T.Y., and Lin H.H. Geographic and ethnic variations of long-term efficacy and immunogenicity of hepatitis B vaccination in Hualien, a HBV hyperendemic area. Vaccine 24 (2006) 4427-4432
6. Al-Faleh F.Z., Al-Jeffri M., Ramia S., Al-Rashed R., Arif M., Rezeig M., et al. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. J Infect Dis 38 (1999) 167-170
7. Hsu H.M., Lu C.F., Lee S.C., Lin S.R., and Chen D.S. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis 179 (1999) 367-370
8. Ayoola A.E., Tobaigy M.S., Gadour M.O., Ahmad B.S., Hamza M.K., and Ageel A.M. The decline of hepatitis B viral infection in South-Western Saudi Arabia. Saudi Med J 24 (2003) 991-995
9. Annarosa F., Vincenzo B., Marco C., Giovanni R., Antonio V., Caterina Z., et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18-year experience in health care workers. Vaccine 22 (2004) 607-610
10. Watson B., West D.J., Chilkatowsky, Percy S., and Ioli V.A. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 19 (2001) 3164-3168
11. Ni Y.H., Chang M.H., Chen P.J., Tsai K.S., Hsu H.Y., Chen H.L., et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e-antigen seroconversion. Gastroenterology 132 (2007) 2340-2345
12. Yuen M.F., Lim W.L., Cheng C.C., Lam S.K., and Lai C.L. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology 29 (1999) 924-927
13. Kunal Das R.K., Gupta V., and Kumar P.K. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over the age of forty years and response of a booster dose among nonresponders. World J Gastroenterol 9 (2003) 1132-1134
14. Yen Y.H., Chen C.H., Wang J.H., Lee C.M., Changchien C.S., and Lu S.N. Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan). Liver Int 25 (2005) 1162-1168
15. Chen H.L., Chang M.H., Ni Y.H., Hsu H.Y., Lee P.I., Lee C.Y., et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 276 (1996) 906-908
16. Grob P., Jilg W., Bornhak H., Gerken G., Gerlich W., Günther S., et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 62 (2000) 450-455
17. Fitzsimons D., François G., Hall A., McMahon B., Meheus A., Zanetti A., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 23 (2005) 4158-4166
18. Kao J.T., Wang J.H., Hung C.H., Hu T.H., Lee C.M., Hung S.F., et al. Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C-endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination. Liver Int 28 (2008) 1298-1304
19. Lu S.N., Chen C.H., Chen T.M., Lee P.L., Wang J.H., Tung H.D., et al. Hepatitis B virus infection in adolescents in a rural township 15 years subsequent to mass hepatitis B vaccination in Taiwan. Vaccine 24 (2006) 759-765
20. Gabbuti A., Romanò L., Blanc P., Meacci F., Amendola A., Mele A., et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 25 (2007) 3129-3132
21. Lee P.I., Lee C.Y., Huang L.M., and Chang M.H. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e-antigen. J Pediatr 126 (1995) 716-721
22. Banatvala J., Van Damme P., and Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 19 (2000) 877-885
23. Jilg W., Lorbeer B., Schmidt M., Wilske B., Zoulek G., and Deinhardt F. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 2 (1984) 1174-1175
24. Dentico P., Buongiorno R., Volpe A., Zavoianni A., Pastore G., and Schiraldi O. Long-term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults. Eur J Epidemiol 8 (1992) 650-655
25. Braito A, Bianchini AM, Mattei C, Benci A, Marri D, Toti M. Decline of HBsAg antibodies after immunization with hepatitis B vaccines and after natural infection. Boll Ist Sieroter Milan. 1991-92; 70: 449-451.
26. West D.J., and Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14 (1996) 1019-1027
27. Mast E.E., Margolis H.S., Fiore A.E., Brink E.W., Goldstein S.T., Wang S.A., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 54 (2005) 1-31
28. Samandari T., Fiore A.E., McMahon B., Negus S., Homan C., Williams J.L., et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. In: Infectious Disease Society of America Annual Meeting. San Francisco, CA (2005)
29. Oliveira M.D., Martins R.M., Matos M.A., Ferreira R.C., Dias M.A., Carneiro M.A., et al. Seroepidemiology of hepatitis B virus infection and high rate of response to hepatitis B virus Butang vaccine in adolescents from low income families in Central Brazil. Mem Inst Oswaldo Cruz. 101 (2006) 251-256
30. Fang J.W., Lai C.L., Chung H.T., Wu P.C., and Lau J.Y. Female children respond to recombinant hepatitis B vaccine with a higher titer. J Trop Pediatr 40 (1994) 104-107
31. Chen C.C., Yen C.H., Wu W.Y., Hu S.W., Chen S.C., Bell W.R., et al. Epidemiology of hepatitis B virus infection among young adults in Taiwan, China after public vaccination program. Chinese Med J 120 (2007) 1155-1158